Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
axsm · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Axsome Therapeutics, Inc. (AXSM) measures how much investors pay for each dollar of the company's trailing earnings. AXSM's current PE ratio of N/A is calculated by dividing its stock price of $232.32 by its TTM earnings per share of -$3.68.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Axsome Therapeutics, Inc.You AXSM | $12.0B | N/A | — | -$3.68 |
 Abivax S.A. ABVX | $6.7B | N/A | — | -$4.83 |
 Arrowhead Pharmaceuticals, Inc. ARWR | $10.3B | N/A | — | -$0.01 |
 CRISPR Therapeutics AG CRSP | $5.0B | N/A | — | -$6.47 |
 Cytokinetics, Incorporated CYTK | $8.9B | N/A | — | -$6.54 |
 Jazz Pharmaceuticals plc JAZZ | $15.0B | N/A | — | -$5.84 |
 Merus N.V. MRUS | $6.8B | N/A | — | -$3.24 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.68 | — | |
2024-12-31 FY2024 | — | $-5.99 | — | |
2023-12-31 FY2023 | — | $-5.27 | — | |
2022-12-31 FY2022 | — | $-4.60 | — | |
2021-12-31 FY2021 | — | $-3.47 | — | |
2020-12-31 FY2020 | — | $-2.77 | — | |
2019-12-31 FY2019 | — | $-2.01 | — | |
2018-12-31 FY2018 | — | $-1.15 | — | |
2017-12-31 FY2017 | — | $-1.27 | — | |
2016-12-31 FY2016 | — | $-1.42 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Axsome Therapeutics, Inc. (AXSM) measures how much investors pay for each dollar of the company's trailing earnings. AXSM's current PE ratio of N/A is calculated by dividing its stock price of $232.32 by its TTM earnings per share of -$3.68.
Frequently asked questions
AXSM pe ratio · 6 questionsAXSM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $232.32 and TTM EPS of -$3.68. Data sourced from Financial Modeling Prep via AXSM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Axsome Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08